Monday, Credit Suisse upgraded Salix Pharmaceuticals Ltd. (SLXP) shares to Outperform from Neutral and increased its price target to $14 from $11. The brokerage widened its 2009 loss per share estimate to $0.71 from $0.65. The brokerage increased its 2010 EPS estimate to $0.30 from $0.25, its 2011 estimate to $0.90 from $0.61, and its 2012 estimate to $1.39 from $0.78.
Analyst Hirsch upgraded the stock to Outperform and increased its price target to $14 based on discounted cash flow which reflects a 13x P/E multiple of his 2011 cash EPS of $1.06. The analyst has updated his 2009 loss per share estimate to reflect sales force expansion which moves his 2009 estimate from a loss of $0.65 to loss $0.71. However, the analyst increased estimates all largely based on Xifaxan growth for the HE (Hepatic Encephalopathy) indication.
While not a new product, Xifaxan for HE is a new product story with Orphan drug status offering 7 years of exclusivity. The analyst expects the usage paradigm and managed care coverage to expand with the indication which could drive revenues from roughly $100 million to over $300 million.
The analyst said that while this is still mostly a one-product story, the bowel cleansing line, new products including Apriso and Metozolv, and a growing niche gastroenterology salesforce combine with Xifaxan to make an attractive specialty pharma asset.
Xifaxan for the IBS indication is one-step further away, but a big market opportunity. The analyst is comfortable with the valuation from HE growth alone to get him aggressive, making IBS a relatively free option for the stock.
Salix has been a bit of a roller coaster over the last year as the company was in transition following the generic loss of its previous lead product Colazal in December 2007. Since then, it's been a balancing act and the analyst weighed a lot of moving numbers and the generic risk to Xifaxan with potential upside from new indications in HE and IBS.
With strong PIII data now out, a sNDA filing expected shortly, less generic risk, and IBS data expected year-end, the analyst believes positive catalysts and revenue growth makes the risk / return profile attractive.
Currently, SLXP is up $0.24 or 2.43% and trading at $10.11.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.